Abstract

To analyse angiogenic factor expression with immunohistochemistry. Skin biopsies from those with psoriasis vulgaris and those without were analysed for levels of vascular endothelial growth factor, Von wille brand factor and CD 34. Finding the degree of neovascularization in skin samples from patients with and without psoriasis vulgaris by comparing the levels of CD 34, VEGF and vWFr. In an effort to link the expression of angiogenesis-promoting factors with the clinical severity of psoriasis as defined by the psoriasis area and severity index (PASI SCORE). Method: A case-control study conducted between July 2022 to February 2023 at tertiary care Centre. There was a total of 43 participants, including both those with psoriasis and healthy skin who acted as controls. Those who have just been diagnosed with psoriasis or who have ceased therapy for at least two months prior to the study are biopsied. Histopathology testing established a diagnosis of psoriasis vulgaris. Immunohistochemistry was used to examine the levels of vascular endothelial growth factor (VEGF), von Willebrand factor (vWF) and CD 34. Result: There was a statistically significant increase in epidermal VEGF expression in patients compared to controls (P=0.01). A higher level of CD 34 expression was seen in the study's patients compared to the controls. (p<0.01). Both the patients and the controls had low levels of von Willebrand factor expression. As with PASI score, VEGF and CD 34 expression were positively connected with PASI score (r=0.944, p0.05), as was VEGF expression and PASI score (r=0.942, p0.05). Conclusion: A substantial difference in VEGF and CD 34 expression was observed between patients and controls. Keratinocytes in psoriatic skin lesions secrete pro-angiogenic cytokines, which encourage microangiopathic changes in the psoriatic plaque. Vascular endothelial growth factor (VEGF) is one type of cytokine. Angiogenesis is implicated in both the aetiology and development of psoriasis vulgaris. Hence, it appears that the development of targeted anti-angiogenic therapy for this chronic, disabling skin disease would be beneficial.

Description